

## INDEX

---

Note: PH stands for pulmonary hypertension;

PAH for pulmonary arterial hypertension.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

Clinical trials are indexed under the acronym of the name.

- 6MWD (6-minute walk distance)
  - effect of exercise on, 213
  - effect of riociguat on, 193-194, 195, 195t, 196, 197, 198t
  - effect of sildenafil and tadalafil on, 181-183, 182, 185
  - in evaluation of treatment efficacy, 101-107, 116, 283, 285t, 286-287
  - goal level, 114, 119, 284t, 287
  - PAH risk and, 36, 112t
  - predictive value of, 286-287
- Activin A receptor type II-like 1 (ACVRL1), 34, 81
- Acute pulmonary hypertension, 239-242, 240
  - right heart failure in, 241, 244-245, 246t
- Acute respiratory distress syndrome (ARDS), 239, 241, 249
- Acute respiratory failure, 251-253, 252
  - extracorporeal life support, 253, 255-256
- Acute vasodilator testing (AVT), 270, 271
- Acute vasoreactivity test, 102, 110-111
- Adempas. See *Riociguat*.
- Adenosine, 62, 110
- Adjunctive therapy and supportive care for PAH, 203-216
  - anticoagulants, 206-209
    - cardiopulmonary rehabilitation, 211-212
    - digoxin, 211
    - diuretics, 203-206
    - in pediatric patients, 276-277
    - supplemental oxygen, 209-210, 213
- Advanced care practitioner, 295-296, 296t, 297
- Age, PAH and, 31-32, 35, 44
- Air travel, 292-293
- Altitude, hypoxia and, 268, 292, 293
- AMBITION trial, 116-118, 117
- Ambrisentan, 160-165, 166t, 275. See also *Endothelin receptor antagonists (ERAs)*.
  - action mechanism, 160
  - adverse reactions, 163-164, 166t
  - AMBITION trial, 116-118, 117
  - CYP interactions, 156t
  - dosing information, 156t, 166t
  - drug interactions, 169, 170t, 171t, 172
  - efficacy and safety, 160-166, 163
    - ARIES-1 trial, 160-163, 163
    - ARIES-2 trial, 163-164, 164
    - ARIES-3 study, 164-165, 165
    - ARIES-E (extension study), 164, 165
  - as initial treatment for PAH, 116-118, 117
  - with PAH of various etiologies, 164-165, 165
  - indications for, 104t, 160, 172
  - in combination with sildenafil, 108t

- Ambrisentan, indications for (*continued*)  
 in combination with tadalafil, 106t, 116-118, 117  
 FDA approved uses, 172  
 monitoring information, 166t  
 pharmacokinetic characteristics, 156t  
 receptor binding, 154, 156t, 160, 275  
 when to discontinue, 166t
- Aminorex, 18, 35, 37t
- Aminotransferase. See *Liver aminotransferase*.
- Amlodipine, 274
- Amphetamines, 18, 31, 37, 37t
- Angiography, 58-60, 222-225, 270
- Anticoagulants, 25, 206-209, 214. See also *Platelet aggregation*.  
 agents  
 other than warfarin, 208-209  
 warfarin, 207-209, 208  
 for CTEPH, 100, 217, 228  
 ERA interactions with, 171t  
 hypercoagulable state in PAH, 206  
 in IPAH, 207, 208, 209  
 treatment recommendations, 100, 209
- Antifungals, 171t
- Antihypertensives, 100
- Anxiety, 291
- Aortic valve calcification, 93
- APAH-CHD, 40-41
- Appetite suppressants, 18, 31, 35, 37t
- ARIES-1 trial, 160-163, 163
- ARIES-2 trial, 163-164, 164
- ARIES-3 study, 164-165, 165
- ARIES-E (extension study), 164, 165
- Arterial blood gas, 270
- Aspirin, 209
- Atrial natriuretic peptide (ANP), 177, 178
- Atrial septostomy, 255  
 for pediatric patients, 277
- Autoimmune thyroiditis, 26
- Beraprost, 104t, 147-148
- Biomarkers, 61-62
- BMPR2. See *Bone morphogenic protein receptor-2*.
- BNP. See *Brain natriuretic peptide*.
- Bone morphogenic protein receptor-2 (BMPR2), 18, 33, 34, 44, 81, 267-268
- Borg Dyspnea Scale, 194-196, 195t, 198t
- Bosentan, 157-160, 162t. See also *Endothelin receptor antagonists (ERAs)*.  
 adverse events, 159-160, 162t, 169  
 CYP interactions, 156t  
 dosing information, 156t, 162t  
 drug interactions, 169, 170t, 171t, 172  
 with sildenafil/tadalafil, 170t  
 efficacy and safety, 119, 121, 157-160, 158  
 BREATHE-1 trial, 157-159  
 BREATHE-5 trial, 159  
 EARLY study, 159-160, 161  
 indications for, 104t, 157, 172  
 in combination therapy, 106t, 108t  
 for CTEPH, 230-231
- Bosentan, indications for (*continued*)  
 FDA approved uses, 172  
 in pediatric patients, 275  
 liver aminotransferase, 159, 162t, 169  
 monitoring information, 162t  
 pharmacokinetic characteristics, 156t  
 receptor binding, 154, 156t, 157, 274  
 when to discontinue, 162t
- Brain natriuretic peptide (BNP), 61-62, 177, 178, 274  
 monitoring and follow-up, 284t, 285t, 287-288
- BREATHE-1 trial, 157-159
- BREATHE-5 trial, 159
- Bronchodilators, 100
- C-type natriuretic peptide (CNP), 178
- Calcification  
 of aortic valve, 93  
 of pulmonary arteries, 73, 75, 76
- Calcium-channel blockers (CCBs), 62, 102, 271-274  
 indications and efficacy, 104t, 110, 271-274  
 in pediatric patients, 271-274
- CAMPHOR Quality of Life questionnaire, 231
- Capillary hemangiomatosis, 16t, 17, 19, 92  
 causes and findings, 59t, 80t, 92, 96-97
- Carbon monoxide, diffusing capacity of the lung (Dl.co), 57  
 in CTEPH, 221
- Cardiac index, 289
- Cardiac magnetic resonance (CMR), 60-61
- Cardiac output, 30, 239  
 atrial septostomy and, 255  
 diuretics and, 204-205  
 iloprost effect on, 143  
 increased, 25, 30, 64  
 liver disease and, 39  
 measurement of, 64  
 mPAP and, 14  
 in PH/PAH, 25, 30, 30, 39, 64, 111, 241  
 outcomes and, 32, 35  
 PVR and, 19
- Cardiopulmonary exercise testing, 112t, 284t, 285t, 287
- Cardiopulmonary rehabilitation, 211-212, 291
- Cardiopulmonary resuscitation (CRP), 256, 292  
 “do not resuscitate” order, 292
- Catheterization. See *Right heart catheterization*.
- Central venous pressure (CVP), 243, 257
- CHEST-1 trial, 193-196, 194, 195t, 229
- CHEST-2 trial, 196
- Chest radiography, 53, 69-70, 70, 270. See also *Radiography*.  
 congenital shunts, 80-81  
 for CTEPH, 221
- Children, PH in, 266-277. See also *Pediatric patient*.  
 causes of, 263, 266-269  
 diagnostic studies, 270, 272-273  
 mPAP for definition of, 263  
 symptoms, 269, 269t  
 treatment, 271-277
- Chronic hemoglobinopathies, 39-40

Chronic obstructive pulmonary disease. See *COPD*.

Chronic thromboembolic pulmonary hypertension (CTEPH), 24-25, 217-238

- causes of, 24, 269
- characteristics of, 217
  - abnormal V/Q scan, 217, 218, 222, 223
  - single or recurrent PE, 217
- classification with PEA, 226, 227t
- clinical presentation, 41-42, 219-220, 220t
- exercise intolerance, 219-220
- exertional dyspnea, 219-220
- findings on physical exam, 220
- heart sounds, 220
- prior history, 219, 221
- diagnosis and evaluation, 221-225, 232
  - distinguishing from other forms of PH, 217, 220t
  - excluding from PH diagnosis, 58
  - physical examination, 220
  - workup, 221-225, 232
    - chest X-ray, 221
    - CT pulmonary angiography (CTPA), 222-224, 224
    - MRI of pulmonary vessels, 224-225
    - pulmonary angiography, conventional, 225
    - pulmonary function testing, 221
    - right heart catheterization, 225, 270
    - transthoracic echocardiography (TTE), 222
    - V/Q scanning, 58, 75, 218, 220t, 222, 223, 270
- imaging of, 74-77, 76, 77t, 221-225
  - contrast CT angiography, 58-59, 60
  - ground glass attenuation, 76
  - mosaic attenuation, 74, 77, 79
  - parenchymal findings, 74, 77, 77t
  - pulmonary webs, 75, 79
  - vascular findings, 74-77, 76, 77t
- incidence of, 26, 217-218
- morbidity and mortality, 217
- mPAP >25 mm Hg, 217, 232
- pathogenesis and risk factors, 218
  - perfusion defects on V/Q scan, 218
  - platelets and coagulation, 218
- pulmonary embolism, disturbed resolution of, 217-218, 219, 220t
- pulmonary embolism or thrombosis, 218, 221, 232
- pulmonary embolism (PE) and, 217-218, 219, 220t
  - confirming presence of, 221, 222-224
- screening for, 42, 218, 221-225
- shunts in, 76-77
- treatment, 100, 225-232
  - anticoagulants, 25, 100, 228
  - bosentan, 230-231
  - endothelin receptor antagonists (ERAs), 230-231
  - epoprostenol, intravenous, 229-230
  - iloprost, inhaled, 230
  - lung transplantation, 228
  - medical therapy (medications), 228-232
  - outcomes of, 217
  - phosphodiesterase-5 inhibitors, 231-232
  - prostacyclin analogues, 229-230
  - pulmonary artery endarterectomy (PEA), 225-228, 232

Chronic thromboembolic pulmonary hypertension (CTEPH), treatment (*continued*)

- riociguat, 100, 119, 191, 201, 229, 233
    - CHEST-1 trial, 193-196, 194, 195t, 229
  - sGC stimulators (riociguat), 100, 191-202, 229, 233
  - sildenafil, 231-232
  - surgery (PEA), 225-228
    - eligibility for, 226, 226t, 232
    - treprostamol, subcutaneous, 230
  - as WHO Group 4, 16t, 24-25, 100, 217, 232
- Cigarette smoking, 120
- Cirrhosis, 39, 89
- Classification of pulmonary hypertension (PH), 15-25, 16t-17t, 26
- Dana Point classification, 15, 16t-17t
- GROUP 1: PAH (pulmonary arterial hypertension), 16t, 17-21, 26, 44, 99
  - functional capacity, classification by, 19-21, 22t, 44
  - medications for, 27, 44, 100
  - treatment approach, 99-119, 100
- GROUP 1[""]: pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomas (PCH), 16t, 17, 19
- GROUP 1[""]: persistent PH of the newborn (PPHN), 16t, 263-266
- GROUP 2: PH due to left heart disease, 16t, 21-23
  - congenital cardiomyopathies, 263
- GROUP 3: PH due to lung diseases and/or hypoxia, 16t, 23-24
- GROUP 4: chronic thromboembolic PH (CTEPH), 16t, 24-25, 217, 232
- GROUP 5: PH with unclear multifactorial mechanisms, 17t, 25-26
- treatment/medication decisions and, 27, 29, 44, 99, 123
- general schematic, 100
- WHO classification groups, 14-26, 16t-17t, 47
  - treatment/medication decisions and, 27, 29, 44, 99

Clinical presentation of PAH, 42-44, 43t

multifactorial PH and, 29

"textbook" presentations, 29

Cocaine, 18, 37

Collagen vascular diseases, 84

Computerized tomography (CT), 58-60, 59t

angiography, 71, 72-73

causes of PH and findings, 59t, 93

chronic pulmonary emboli on, 93, 222-224, 224

congenital shunts, 81

CT pulmonary angiography (CTPA), 222-224, 224

for CTEPH, 222-224, 224

findings in IPAH, 74t

Congenital heart defects, 266-267

Congenital heart diseases, 19, 20t, 21t

PAH associated with (APAH-CHD), 40-41

PAH risk and, 40-41

as subgroup of WHO Group 2, 263

Congenital systemic-to-pulmonary shunts, 19, 20t, 21t, 77-83, 82-83.

See also *Shunts*.

causes of, 77-80

imaging of, 77-83, 82-83

chest radiography, 80-81

CT findings, 59t

progression to PH, 80

pulmonary arteriovenous malformations (PAVMs), 81-83

Connective tissue disease, 18  
collagen vascular diseases, 84  
PAH risk and, 32, 38  
serologic testing for, 61

Continuous positive airway pressure (CPAP), 100

COPD (chronic obstructive pulmonary disease), 23-24, 87  
causes and findings, 80t, 87  
CT findings, 59t  
digoxin and, 211  
NOTT trial, 209-210  
sildenafil cautions in, 121  
supplemental oxygen in, 209-210

Cor pulmonale, 120, 251

CPAP (continuous positive airway pressure), 100

CREST variant, 38

Critically ill patients. See *ICU, pulmonary hypertension in.*

CTEPH. See *Chronic thromboembolic pulmonary hypertension.*

Cutaneous scleroderma, 38

Cyclic AMP (cAMP), 179, 188  
prostacyclin and, 129

Cyclic GMP (cGMP), 177, 178, 179, 275  
NO/cGMP signaling pathway, 191, 192

Cytochrome P450 pathway, 169

Daily living, activities of, 291

Dana Point classification system, 15, 16t-17t

Dasatinib, 37t

Dead space ventilation, 220

Definitions and classification, 13-28. See also *Classification of pulmonary hypertension.*  
classification system, 15-25, 16t-17t, 26  
Dana Point classification, 15, 16t-17t  
pulmonary hypertension as mPAP >25 mm Hg, 13, 14, 26

Depression, 291

Dexfenfluramine, 35, 37t

Diagnosis, 47-68  
algorithm for, 50-51  
diagnostics, 49-64, 65. See also *Radiography.*  
arterial blood gas, 270  
biomarkers, 61-62  
cardiac catheterization, 62-64, 270  
cardiac magnetic resonance (CMR), 60-61  
chest radiography, 53, 270  
computerized tomography (CT), 58-60, 59t  
echocardiography, 53-57, 54, 270  
sPAP calculation and measurement, 53-54  
transthoracic echocardiography (TTE), 48, 53-57, 65, 65  
electrocardiography (EKG), 49-53, 52, 270  
pulmonary angiography, 58-60, 225, 270  
pulmonary function tests (PFTs), 57, 270  
right heart catheterization, 62-64, 65, 270  
sleep study, 66  
vasodilator testing, 62-64, 65  
ventilation-perfusion (V/Q) scan, 58, 222, 270  
early diagnosis, 65  
history, 49  
late diagnosis, 47, 48

Diagnosis (*continued*)  
in pediatric patient, 270, 272-273  
physical exam, 49  
screening for PH, 48, 57  
signs and symptoms, 48-49  
in infants and children, 269t  
timing of, and clinical outcomes, 47-48, 65

Diet control, amphetamine use, and PAH, 18, 31, 35

Diffusing capacity. See *Carbon monoxide.*

Digoxin, 211  
ERA interactions with, 171t  
in pediatric patients, 276

Diltiazem, 274

Direct thrombin, 208

Diuresis, 248, 257

Diuretics, 203-206, 213  
indications for, 100, 203-204  
individual titration of therapy, 205-206  
in pediatric patients, 276  
potassium supplements and, 205-206  
RV function and, 204, 205  
treatment goals for, 204

“Do not resuscitate” order, 292

Dobutamine, 248-249, 257

Dopamine, for PPHN, 265

Drug- and toxin-related PAH, 16t, 18, 35-37, 37t

Dyspnea, 29, 42, 48  
exertional dyspnea, 219-220, 269

Dysrhythmias, 253-254

EARLY study, 159-160, 161

Echocardiography, 53-57, 54, 270, 285t, 288  
assessment of geometric relationship between ventricles, 247  
assessment of right ventricular function, 56-57, 56  
causes of PH, identification with, 57  
contrast echocardiography, 54-55  
follow-up, 285t, 288  
goal-directed (GDE), 243-247, 257  
information from, 53, 57, 288  
negative results, meanings of, 55  
transthoracic echocardiography (TTE), 53-57, 65, 65, 69  
in screening for PH, 48, 57  
sPAP calculation and measurement, 53-54  
tricuspid annular plane systolic excursion (TAPSE) and, 47

ECMO (extracorporeal membrane oxygenation), 255-256, 266

Edema, 32  
peripheral, 269  
diuretics for, 203-206  
with ERAs, 168-169  
pulmonary, 92  
PAH-specific medications and, 92

Education for patient, 296t

Eisenmenger syndrome, 19, 21t, 40, 77, 267  
causes and findings, 80t, 82-83

Electrocardiography (EKG), 49-53, 52, 270

Emphysema, 120, 121

- End of life care, 292
- Endoglin, gene mutations, 34, 81
- Endothelin (ET-1), 153, 172
- action mechanism, 153-154, 155
  - actions of, 153-154, 155
    - vasoconstriction, 153, 155, 172
    - vasodilation, 154, 155, 160
  - PAH and, 154, 155
  - receptors, 153-154, 155, 156t, 275
    - ET-A receptors, 153-154, 155, 275
    - ET-B receptors, 153, 154, 155, 275
  - synthesis, factors regulating, 154
  - synthesis, inhibitors of, 154
- Endothelin receptor antagonists (ERAs), 153-175. See also *specific agents*.
- action mechanism, 153-154, 155
  - adverse effects, 168-172
    - drug interactions, 169, 170t, 171t, 172
  - agents
    - ambrisentan, 160-165, 166t
    - bosentan, 157-160, 162t
    - macitentan, 165-168, 168t
  - cautions and contraindications, 169-172, 250
  - CYP interactions, 156t, 170t
  - cytochrome P450 pathway and, 169
  - dosing information, 162t, 166t, 169t
  - drug interactions, 169, 170t, 171t
  - efficacy, study of, 107
  - indications for, 104t, 114, 154, 172
    - in combination therapy, 106t, 108t, 114, 116
      - as initial therapy for PAH, 118, 123, 154
      - for critically ill patients with PH, 250
      - for CTEPH, 230-231
      - in pediatric patients, 275
        - WHO Group 1 (PAH), 100
    - liver aminotransferase, 159, 162t
    - monitoring information, 162t, 166t, 168t, 172
    - in overall approach to patient, 100
    - PAH and, 154, 155
    - in pediatric patients, 275
    - pharmacokinetic characteristics, 156t
    - pregnancy cautions, 169-172
    - receptor binding, 154, 155, 156t, 275
      - dual receptor binding (bosentan), 154, 156t, 275
      - ET-A selective (ambrisentan, macitentan), 154, 156t, 160
    - when to discontinue, 162t, 166t, 169t
- Environmental factors, 35-42. See also *Epidemiology of PH/PAH*.
- Epidemiology of PH/PAH, 29-42
- age and, 31-32, 44
  - anorectic amphetamine use and, 31
  - case registries/databases and, 31
  - clinical presentation, 29, 42-44, 43t
    - associated features, 31
    - characteristics of PAH, 31, 42-44
  - family history of PAH, 31
  - gender and, 31, 32, 45
  - heritability, genetics, and environmental factors, 33-42, 44
    - chronic hemoglobinopathies, 39-40
  - Epidemiology of PH/PAH; heritability, genetics, and environmental factors (*continued*)
    - congenital heart disease, 40-41
    - connective tissue disease, 38
    - CTEPH, 41-42
    - drug- and toxin-related PAH, 35-37, 37t
    - hemolytic anemias, 39-40
    - heritability and mutations, 33-35, 44
    - HIV, 38-39
    - portal hypertension (PPH), 39
    - pulmonary veno-occlusive disease, 41
    - sickle cell disease, 39-40
    - incidence of PAH, 31
    - natural history of PH, 29, 30, 30
    - risk assessment, 32-33, 33
      - factors associated with poor outcome, 32
      - REVEAL risk calculator, 32-33, 36-37, 290
    - survival rates, 31, 32, 33, 45
- Epoprostenol. See also *Prostacyclin therapy*.
- action mechanism, 128-129, 274
  - commercial products (generic, Flolan, Veltri), 130t
  - delivery devices, 130t
  - dosage, 134-136
  - effects of, 128
  - efficacy of, 127, 131-133, 133, 149
  - FDA approval for PAH, 127
  - formulations, 134
  - half-life, 129
  - indications for, 102-103, 104t, 149
    - in combination therapy, 106t, 108t, 116
    - for critically ill patients with PH, 250
    - for CTEPH, 229-230
    - as initial therapy, 131
      - in pediatric patients, 274
  - infusion pumps, 134, 135
  - inhaled, 250, 257
  - intravenous, 130t, 132-138
    - indications for, 104t, 115, 229-230
      - for critically ill patients with PH, 250
    - infusion pump for, 134, 135
  - in pediatric patients, 274
  - stability, 130t, 134
    - heat-stable form, 129, 134
  - synthesis of, 128
  - vs prostaglandin E<sub>1</sub>, 128
- ERA. See *Endothelin receptor antagonists (ERAs)*.
- ESC/ERS treatment recommendations, 101, 102-103, 104t-106t, 108t-109t
- Exercise capacity
- exercise program for PAH, 212, 213
  - phosphodiesterase-5 inhibitors and, 181-183
  - sildenafil/tadalafil and, 181-183
- Exercise intolerance, 29, 219-220
- Exercise recommendations, 212, 213, 291
- Exercise testing, 284t, 285t, 287
- risk level and, 112t
- Exertional dyspnea, 219-220, 269

Extracorporeal life support, 253, 255-256  
Extracorporeal membrane oxygenation (ECMO), 255-256

Factor Xa inhibitors, 208

Fatigue, 29, 42, 48

Fenfluramine, 18, 35, 37t

Fenfluramine/phentermine phentolamine (fen-phen), 18

Fetal circulation, 264

FEV<sub>1</sub>, 57

FEV<sub>1</sub> to FVC ratio, 57

Fibrosis. See *Mediastinal fibrosis; Pulmonary fibrosis.*

Flolan, 130t. See also *Epoprostenol.*

Flu vaccine, 289-291

Fluid responsiveness, 243-247

Follow-up of PAH patient, 123, 283-299. See also *Monitoring recommendations.*

advanced care practitioner, 295-296, 296t, 297

air travel, 292-293

cardiopulmonary exercise testing, 284t, 285t, 287

echocardiography, 285t, 288

exercise, 291

frequency and type of monitoring, 284, 285t, 297

lung transplantation, 294-295

NT-proBNP, 285t, 287-288

obtaining medication, 294

palliative/end of life care, 292, 297

psychosocial issues, 291, 297

right heart catheterization, 285t, 289

treatment goals, 284, 284t

treatment success, evaluation of, 283-284, 284t

vaccinations and, 289-291

WHO functional class, 286

Forced expiratory volume in one second (FEV<sub>1</sub>), 57

Functional assessment of PAH, 286-287

Functional classes (WHO), 19-21, 22t, 44, 286

follow-up and, 286

goal level, 114, 284t

risk level and, 111-115, 112t-113t

treatment recommendations based on, 104t-105t, 106t

G-proteins, 128-129, 153

Gastroesophageal reflux disease (GERD), 269

Gaucher's disease, 26

Gender, PAH and, 31, 32, 45

Genetics, 16t, 18, 33-35

mutations, 18, 33-35, 44, 81

GERD (gastroesophageal reflux disease), 269

Glycogen storage disorders, 26

Goal-directed echocardiography (GDE), 243-247

Ground glass attenuation, 76

Ground glass nodules, 92, 96-97

Ground glass opacities, 92

GROUP 1: PAH (pulmonary arterial hypertension), 16t, 17-21, 26, 44, 99

medications for, 27, 44, 100

treatment approach, 99-119, 100, 123

treatment recommendations, 101, 102-103, 104t-106t, 108t-109t

GROUP 2: PH due to left heart disease, 16t, 21-23

congenital cardiomyopathies, 263

treatment approach, 100, 119-121

GROUP 3: PH due to lung diseases and/or hypoxia, 16t, 23-24

treatment approach, 100, 119, 120-121

GROUP 4: chronic thromboembolic PH (CTEPH), 16t, 24-25, 217, 232

treatment approach, 100

GROUP 5: PH with unclear multifactorial mechanisms, 17t, 25-26

treatment approach, 100, 119, 122-123

Guanylate cyclase stimulators, 191-202. See also *Soluble guanylate cyclase stimulators.*

Heart sounds, in CTEPH, 220

Hemodynamics, 116

risk level and, 113t

treatment goals, 284t

Hemoglobinopathies, chronic, 39-40

Hemolytic anemias, 25, 39-40

Heparins, 208, 209

Hepatitis, testing for, 61

Hepatopulmonary syndrome, 89-90

causes and findings, 59t, 80t, 89-90

Hereditary hemorrhagic telangiectasias (HHT), 81

Heritability of PAH, 33-35, 44

family history of PH, 33

mutations, 33-35, 44, 81, 267-268

Heritable PAH (HPAH), 16t, 18, 35, 44

mutations in, 268

pediatric patients and, 263, 268

High altitude, hypoxia and, 268, 292, 293

HIV (human immunodeficiency virus), 38-39, 88-89

causes and findings, 59t, 80t

and PH/PAH, 38-39, 88-89

diagnosis, 88-89

prognosis, 38-39

testing for, 61

Honeycombing, 83-84, 86-87

HPAH. See *Heritable PAH.*

Hypercoagulable state, 206

Hypokalemia, 205-206

Hypothyroidism, 26

Hypoxemia, 213, 265

nocturnal, 276

Hypoxia

alveolar, 251

chronic, 268

high altitudes and, 268, 292, 293

PH due to, 16t, 23-24, 120-121, 209

vasoconstriction and, 251

ICU, pulmonary hypertension in, 239-262

acute pulmonary hypertension, 239-242

acute respiratory failure, 251-253, 252

extracorporeal life support, 253, 255-256

cardiopulmonary resuscitation (CRP), 256, 292

"do not resuscitate" order, 292

dysrhythmias, 253-254

- ICU, pulmonary hypertension in (*continued*)
- key points, 257
  - mortality rates in PH patients in ICU, 254, 256
  - nitric oxide and pulmonary vasodilators, 249-251
  - outcomes, 256, 257
  - positive end-expiratory pressure (PEEP), 253
  - rescue therapies, 255-256
    - atrial septostomy, 255
    - devices to bypass right heart, 255
    - right ventricular assist devices (RVADs), 255
    - veno-arterial extracorporeal membrane oxygenation (V-AECMO), 255-256
  - resuscitation and vasoactive support, 247-249
  - sepsis, 254-255
  - shock, 247-249
  - trauma, 254
  - ventilation, 251-253
  - volume status and fluid responsiveness, estimation of, 243-247, 255, 257
  - central venous pressure (CVP), 243, 257
    - goal-directed echocardiography, 243-247, 257
- Idiopathic fibrosis, 83-84, 86-87
- Idiopathic PAH (IPAH), 16t, 18, 27
- anticoagulants (warfarin) and, 207, 208, 209
  - imaging features of, 72-74, 72-73, 74t
    - mosaic attenuation, 73-74, 75
  - in infants and children, 263, 267-268
- Iloprost (Ventavis), 129, 130t, 131. See also *Prostacyclin therapy*.
- indications for, 104t, 108t
    - for CTEPH, 230
    - in pediatric patients, 274-275
  - routes of administration
    - inhalation, 104t, 130t, 131, 141-146
      - adverse events, 144
        - for CTEPH, 230
      - efficacy of, 141-144, 143t
      - half-life, 141, 142, 144
      - nebulizers for, 141, 144, 145
    - intravenous infusion, 104t, 131
      - not approved for PAH in the U.S., 131
- Infants, PH in, 266-277. See also *Pediatric patient*.
- causes of, 263, 266-269
  - diagnostic studies, 270, 272-273
  - mPAP for definition of, 263
  - symptoms, 269, 269t
  - treatment, 271-277
- Inferior vena cava (IVC) diameter, 246
- Influenza vaccine, 289-291
- Inotropic support, 248-249, 257
- Interdisciplinary team collaboration, 295-296, 297
- Interferon, 37t
- Interventricular septum, 69, 241, 242
- IP receptor agonists, indications for, 104t-105t
- IPAH. See *Idiopathic PAH*.
- Left atrial pressure (LAP), 13
- Left end-diastolic ventricular mass, 60
- Left heart disease, PH due to, 21-23, 26, 41, 93, 267
- treatment approach, 100, 119-121, 124
  - as WHO Group 2, 16t, 24-25
- Left ventricle
- ventricular interdependence in PH, 205, 241, 242
  - ventricular volume, relationships of right and left ventricles, 242
  - ventricular volume changes, pressures and, 240-241, 240
- Left ventricular diastolic dysfunction, 31-32, 41
- Left ventricular end-diastolic area, 247
- Left ventricular end-diastolic pressure (LVEDP), 13, 32, 204, 205
- Left ventricular failure, 267
- Left ventricular function, 205, 241, 242, 254
- Life support, extracorporeal, 253, 255-256. See also *Ventilation*.
- Liver aminotransferase
- increase with ERAs, 159, 169
  - monitoring recommendations
    - ambrisentan, 166t
    - bosentan, 162t, 169
    - macitentan, 168t
- Liver disease, 39, 89. See also *Hepatopulmonary syndrome; Portal hypertension*.
- Liver function tests (LFTs), monitoring recommendations
- ambrisentan, 166t
  - bosentan, 162t, 169
  - ERAs, 162t, 166t, 168t, 172
  - macitentan, 168t
- Liver toxicity, ERAs and, 172
- Lung diseases, PH due to, 23-24, 26
- treatment approach, 100, 119, 120-121, 124
  - as WHO Group 3, 16t, 23-24
- Lung transplant. See *Transplantation, lung*.
- Lymphangioleiomyomatosis (LAM), 88
- Lymphangiomyomatosis, 26
- Macitentan, 165-168, 168t, 275. See also *Endothelin receptor antagonists (ERAs)*.
- action mechanism, 165
  - adverse reactions, 167-168, 168t
  - CYP interactions, 156t
  - dosing information, 156t, 168t
  - drug interactions, 169, 170t, 171t, 172
  - efficacy and safety, 107, 165-168
    - SERAPHIN study, 165-167, 167
  - indications for, 104t, 165, 172
    - in combination therapy, 108t
    - FDA approved uses, 172
  - monitoring information, 168t
  - pharmacokinetic characteristics, 156t
  - receptor binding, 154, 156t, 275
  - when to discontinue, 168t
- Mean PAP (mPAP)
- calculation from sPAP, 54
  - changes during exercise, 14
  - elevated, 17-18, 30, 64
  - in PH (>25 mm Hg), 13, 14, 26, 217
  - in infants and children, 263

Mechanical ventilation, 251. See also *Ventilation*.  
 for PPHN, 266  
 pulse pressure variation (PPV) and, 247

Mediastinal fibrosis, 90  
 causes and findings, 59t, 80t, 90, 91

Medications, obtaining, 294

Milrinone, 249

Mitral stenosis, 267

Monitoring recommendations, 283-299  
 ambrisentan, 166t  
 bosentan, 162t  
 ERAs, 162t, 166t, 168t, 172  
 frequency and type of monitoring, 284, 285t, 297  
 liver aminotransferase, 162t, 166t, 168t  
 macitentan, 168t  
 riociguat, 199t  
 sGC stimulators, 199t

Monoamine oxidase (MAO) inhibitors, 37

Mosaic attenuation, 73-74, 75, 93  
 in CTEPH, 74, 77, 79

MRI  
 phase contrast, 81  
 of pulmonary vessels, 224-225

Multifactorial PH, 17t, 25-26, 29

Murmurs, in CTEPH, 220

Mutations, in PAH, 18, 33-35, 44, 81, 267-268

MVR/AVR, 100

Myocardial volume, 60

NAION (nonarteritic ischemic optic neuropathy), 185-187

Natriuretic peptides, 177-179, 178

Natural history of pulmonary hypertension (PH), 29, 30, 30

Newborns. See *Persistent pulmonary hypertension of the newborn (PPHN)*.

Nifedipine, 274

Nitric oxide (NO), 25, 40, 178, 249  
 inhaled (iNO), 249, 250, 257  
 for PPHN, 265-266  
 inhibition of endothelin synthesis, 154  
 NO/cGMP signaling pathway, 191, 192  
 vasodilation via, 154, 177, 179, 188, 191, 240-250  
 vasodilator testing with, 62

Nitric oxide synthetase (NOS), 177, 179

Nonarteritic ischemic optic neuropathy (NAION), 185-187

Nonspecific idiopathic pneumonia (NSIP), 83-84

Norepinephrine, 248, 257

NOTT trial, 209-210

NSAIDs, ERA interactions with, 171t

NT-proBNP, 112t, 285t, 287-288

O<sub>2</sub>. See *Oxygen*.

Obstructive sleep apnea, 24, 120-121, 268

Older patients, 31-32, 44  
 comorbid conditions in, 31  
 delayed diagnosis in, 31  
 PAH in, 31-32

Orenitram, 130t. See also *Treprostinil*.

Osler-Weber-Rendu syndrome, 81

Oxygen (O<sub>2</sub>), 121, 209-210  
 air travel and, 292-293  
 high concentrations of, to lower PVR, 265  
 hypoxia, effects in PH, 209  
 monitoring, in critically ill patients, 251  
 in overall approach to patient, 100  
 oxygen index, 266  
 partial pressure of oxygen, goal for, 210  
 saturation recommendations, 292-293  
 supplemental oxygen, 209-210, 213  
 for air travel, 293  
 in pediatric patients, 276  
 portable oxygen concentrators, 293  
 for WHO Group 3 (lung diseases), 100

Oxygen-poor environment. See *Hypoxia*.

PA diastolic pressure (dPAP), 41

Palliative/end of life care, 292, 297

PAP. See *Pulmonary arterial pressure*.

PATENT-1 trial, 196-197, 197, 198t

PATENT-2 trial, 197

Patient education, 296t

PDE5Is. See *Phosphodiesterase type-5 inhibitors*.

PE. See *Pulmonary emboli*.

PEA. See *Pulmonary artery endarterectomy*.

Pediatric patient, pulmonary hypertension in, 263-281  
 causes of PH in, 263, 266-269  
 early diagnosis and treatment, 277  
 infants and children, 266-277  
 causes of PH in, 263  
 clinical manifestation, 269, 269t  
 diagnostic studies, 270, 272-273  
 cardiac catheterization, 270, 277  
 epidemiology and etiology, 266, 277  
 congenital heart defects, 266-267  
 Eisenmenger syndrome, 267  
 heritable PAH (HPAH), 263, 268  
 idiopathic PAH (IPAH), 263, 264, 267-268  
 incidence rates, 266  
 registries, 266, 271  
 respiratory disorders, 268-269  
 thromboembolic disease, 269  
 mPAP for definition of PH in, 263  
 presentation, 269-270  
 prognosis, 263, 271, 277  
 symptoms, 264, 269, 269t  
 treatment, 271-277  
 adjuvant therapies, 276-277  
 algorithm for treatment, 278  
 atrial septostomy, 277  
 calcium-channel blockers (CCBs), 271-274  
 combination therapy, 276  
 endothelin receptor antagonists (ERAs), 275  
 goal of, 271  
 lung transplantation, 277  
 phosphodiesterase inhibitors, 275-276



Pediatric patient, pulmonary hypertension in; infants and children; treatment (*continued*)

prostacyclin analogues, 274-275

sildenafil, 275-276

warning for ages 1-17 years, 276

persistent pulmonary hypertension of the newborn (PPHN), 263-266, 277

Perfusion pressure, 248, 257

Pericardial effusion, 288

Pericardium, 241, 242

Peripheral edema, 168-169, 269

diuretics for, 203-206

Peripheral vessels, small tortuous, 72, 72-73

Persistent pulmonary hypertension of the newborn (PPHN), 263-266, 277.

See also *Pediatric patient*.

clinical manifestations, 264

diagnosis, 265

epidemiology and etiology, 263-264

oxygen index in, 266

pathophysiology, 264

as subgroup of WHO Group 1, 16t, 263

treatment, 265-266

ECMO, 266

mechanical ventilation, 266

medications, 265-266

surfactant, 266

PGI<sub>2</sub>. See *Prostacyclin*.

Phase contrast MRI, 81

Phenylephrine, 248

PHIRST trial, 181, 182, 183-185, 186t

Phosphodiesterase-5 inhibitors (PDE5Is), 177-190. See also *specific agents*.

action mechanism, 177-179, 178, 275

adverse effects, 185-187, 186t

acute PE, 185

nonarteritic ischemic optic neuropathy (NAION), 185-187

agents

sildenafil, 179-188

tadalafil, 179-188

vardenafil, 180

cautions and contraindications, 187, 250

drug interactions, 170t

with riociguat, 200-201

effects and metabolism, 179, 180, 187, 275

efficacy in PAH, 179, 180-181, 182, 187-188

6MWD, increase in, 181-183, 182, 185

changes in PVR and, 180, 183

exercise capacity, 181-183

functional class, 184

hemodynamic effects, 183

long-term effect, 184-185

PHIRST trial, 181, 182, 183-185, 186t

SUPER trial, 181, 182, 183-185, 186t

time to clinical worsening, 184

indications for, 104t, 114, 179-181, 187-188

in combination with ERA, 106t, 108t, 109t, 114, 116, 118

as initial therapy for PAH, 118, 123

for critically ill patients with PH, 250

for CTEPH, 231-232

Phosphodiesterase-5 inhibitors (PDE5Is), indications for (*continued*)

for PAH, 100, 180-181, 187-188

in pediatric patients, 275-276

long-term effect of, 184-185

in overall approach to patient, 100

in pediatric patients, 275-276

Phosphodiesterases (PDEs), 178, 179

Physical activity. See *Exercise*.

Platelet aggregation, 206

anticoagulants and, 206-209

CTEPH and, 218

epoprostenol effect on, 128

prostacyclin and, 206, 266

serotonin and, 206

Pneumococcal vaccine, 289-291

Portal hypertension (PPH), 18-19, 39

Positive end-expiratory pressure (PEEP), 253

Positive pressure ventilation, 241, 251, 252

Potassium supplements, 205-206

PPHN. See *Persistent pulmonary hypertension of the newborn*.

Pregnancy

ERA cautions in, 169-172

riociguat cautions in, 200

Risk Evaluation and Mitigation Strategies (REMS), 169-172

Primary PH. See *Idiopathic PAH (IPAH)*.

Prostacyclin therapy, 127-152. See also *specific agents*.

acronym: PGI<sub>2</sub>, 127

action mechanism, 128-129, 206, 266

agent (prostacyclin receptor agonist): selexiprog, 131

agents (prostacyclin analogues), 130t

epoprostenol, 127, 129, 130t

iloprost, 129, 130t, 131

treprostiniol, 129, 130t

cautions and contraindications, 132

delivery devices, 130t, 134, 135, 144, 145

development of, 127-132

dosage, 131, 134-136, 148

efficacy, 101, 115, 131-132, 148-149

inhaled prostacyclin, 141-144, 143t

intravenous, 127, 131-132

non-equivalence of agents, 132, 149

oral and inhaled formulations, 115-116, 131

ESC/ERS recommendations, 101, 104t-105t

extravasation of prostacyclin, 136, 137

indications for, 104t-105t, 115, 123, 148

for critically ill patients with PH, 250

for CTEPH, 229-230

as initial therapy, 131

for PPHN, 266

WHO Group 1 (PAH), 100

infections and, 138

infusion pumps, 134, 135

interruptions of therapy, results of, 136

intravenous, 101, 115, 123, 132-138

central venous access, 136, 138

efficacy of, 131

- Prostacyclin therapy, intravenous (*continued*)  
 infusion pumps for, 134, 135  
 risks of, 115, 138  
 monotherapy with, 104t-105t  
 in overall approach to patient, 100  
 patient characteristics and knowledge for therapy, 136-138  
 in pediatric patients, 274-275  
 platelet aggregation and, 206  
 routes of administration, 130t, 148  
 inhalation (treprostinil, iloprost), 129, 130t, 131, 141-146  
 efficacy, 141-146, 143t  
 nebulizers for, 141, 144, 145  
 intravenous (epoprostenol), 130t, 132-138  
 intravenous infusion (treprostinil, iloprost), 129, 130t, 131  
 oral (beraprost), 147-148  
 oral (treprostinil), 129, 130t, 146-148  
 subcutaneous infusion (treprostinil), 129, 130t, 138-140  
 stability of agents, 130t, 134  
 synthesis of prostacyclin, 127-128  
 tachyphylaxis and, 131, 136  
 thromboxane/prostacyclin ratio, 206
- Prostaglandins, 127
- Protease inhibitors, ERA interactions with, 171t
- Psychosocial issues, 291, 297
- Pulmonary angiography, 58-60, 225, 270  
 CT pulmonary angiography (CTPA), 222-224, 224
- Pulmonary arterial hypertension (PAH), 17-21  
 air travel and, 292-293  
 characteristics of, 31  
 classification of, 16t, 17-21, 26. See also *Classification of pulmonary hypertension*.  
 clinical presentation of, 30, 42-44, 43t  
 PVR in, 30  
 diagnosis, 47  
 epidemiology, 29-42  
 age and, 31-32, 35, 44  
 anorectic amphetamine use and, 31, 35, 37t  
 APAH-CHD, 40-41  
 family history of PAH, 31  
 gender and, 31, 32, 45  
 heritability, genetics, and environmental factors, 33-42  
 HIV, 38-39  
 subtypes based on age, 31  
 follow-up for, 283-299. See also *Follow-up of PAH patient*.  
 heritable PAH, 16t, 18, 35, 44, 263  
 in pediatric patients, 263  
 hypercoagulable state in, 206  
 idiopathic (IPAH), 16t, 17, 18  
 anticoagulants and, 207, 208, 209  
 formerly known as primary PH, 267  
 imaging features of, 72-74, 72-73, 74t  
 in pediatric patients, 263, 267-268  
 vasodilator testing for, 62-63, 65  
 incidence of, 31  
 medications for, 27, 29  
 mPAP elevation in, 17-18, 30  
 natural history, 30
- Pulmonary arterial hypertension (PAH) (*continued*)  
 progression of, 30, 31  
 as progressive disease, 17, 23, 99, 256, 297  
 pulmonary vascular thrombosis in, 206  
 pulmonary vasodilator response, testing for, 107-110  
 risk assessment, 111-115, 112t-113t  
 subtypes, 16t, 17, 31  
 associated with other conditions, 16t, 17  
 drug- and toxin-induced PAH, 16t, 18, 35-37, 37t  
 heritable PAH, 16t, 18  
 idiopathic PAH, 16t, 17, 18, 72-74  
 survival rates, 31, 32, 33, 45  
 treatment, 99-119. See also *Treatment; and specific treatments*.  
 adjunctive therapy and supportive care, 203-216  
 calcium-channel blockers in, 62, 101  
 combination therapy recommendations, 102-103, 106t  
 sequential combination therapy, 108t-109t  
 efficacy, evaluation of, 101-107  
 ERAs (endothelin receptor antagonists), 153-174  
 ESC/ERS recommendations, 101, 102-103, 104t-106t, 108t-109t  
 exercise and, 212, 213  
 functional assessment of, 286-287  
 monotherapy recommendations, 102, 104t-105t  
 obtaining medications, 294  
 overall treatment approach, 99-119, 100, 123  
 phosphodiesterase-5 inhibitors, 177-190  
 prostacyclin therapy, 127-152  
 pulmonary vasodilator response, testing prior to treatment, 107-110  
 soluble guanylate cyclase stimulator (riociguat), 100, 191-202  
 as WHO GROUP 1, 16t, 17-21, 26, 44, 99
- Pulmonary arterial pressure (PAP)  
 causes of elevation, 110, 258  
 mean PAP (mPAP)  
 in PAH (elevated), 17-18, 30  
 clinical detection of, 42  
 in PH (>25 mm Hg), 13, 14, 26, 47, 64, 217  
 in infants and children, 263  
 obstructive sleep apnea and, 268  
 pulmonary artery diastolic pressure (dPAP), 41  
 WHO groups and, 100
- Pulmonary arteries  
 calcification of, 73, 75, 76  
 dilatation of, 69  
 with congenital shunts, 81  
 with pulmonary fibrosis, 86-87  
 enlarged, 70, 70, 72-73  
 in CTEPH, 76  
 diameter >29 mm, 71, 93  
 in HIV, 88-89  
 evaluation with radiology, 69-70, 70  
 Qp:Qs ratio, 81  
 sclerosis of, 14-15, 30
- Pulmonary arteriovenous malformations (PAVMs), 81-83
- Pulmonary artery  
 contrast CT angiography of, 58-60  
 diameter of (dPA), 71  
 enlarged, 70, 70, 72-73, 86-87, 88

Pulmonary artery catheter (PAC), 243

Pulmonary artery endarterectomy (PEA), 225-228
 

- classification of CTEPH with, 226, 227t
- eligibility criteria for, 226, 226t, 232
- operative mortality rates, 227
- PH after, riociguat for, 233
- postoperative complications, 227-228
- treatment goals of, 225-226
- for WHO Group 4 (CTEPH), 100, 225-228

Pulmonary artery systolic pressure (sPAP), 53-54

Pulmonary capillary hemangiomatosis (PCH), 16t, 17, 19, 59t

Pulmonary capillary wedge pressure (PCWP), 13, 32

Pulmonary circulation, 239-240

Pulmonary emboli (PE), 42
 

- acute PE
  - CTEPH after, 217-218
  - disturbed resolution of, 218, 219, 220t
  - on chest X-ray, 221
  - management strategies, 241
  - right heart failure and, 241

Pulmonary fibrosis, 24, 25, 26, 83, 93
 

- causes and findings, 59t, 80t, 83-86, 93
- idiopathic fibrosis, 83-84, 86-87
- imaging of, 83-86, 84-85, 86-87
  - honeycombing, 83-84, 86-87
- sarcoidosis, 84-85, 88-89
- treatment of PH in, 121

Pulmonary function tests (PFTs), 57, 270
 

- in CTEPH, 221

Pulmonary histiocytosis, 26

Pulmonary hypertension (PH)
 

- acute, 239-242. See also *Acute pulmonary hypertension*.
- approach to patient with, 99-126
- causes of, 77t, 80t, 93
  - findings in, 59t, 71, 72-73, 80t
  - identification with echocardiography, 57
- clinical presentation, 29, 42-44, 43t
  - characteristics, 47, 69
  - morphologic findings, 69
  - as mPAP of >25 mm Hg, 13, 14, 26, 47, 64
  - presenting symptoms, 48
  - rise in PVR, 30, 30
- as complication to other conditions, xi
- in critically ill patients, 239-262
- definitions and classification, 13-28, 16t-17t. See also *Classification of PH*.
  - chronic thromboembolic PH (CTEPH), 16t, 24-25, 217
  - functional capacity, classification by, 19-21, 22t
  - in infants and children, 263
  - as mPAP of >25 mm Hg, 13, 14, 26, 47, 217, 263
  - PAH (pulmonary arterial hypertension), 16t, 17-21
  - persistent PH of the newborn (PPHN), 16t, 263-266
  - PH due to left heart disease, 16t, 21-23
  - PH due to lung diseases and/or hypoxia, 16t, 23-24
  - PH with unclear multifactorial mechanisms, 17t, 25-26
  - pulmonary capillary hemangiomatosis (PCH), 16t, 17, 19
  - pulmonary veno-occlusive disease (PVOD), 16t, 17, 19
  - WHO groups, 14-26, 16t-17t, 47

Pulmonary hypertension (PH) (*continued*)
 

- diagnosis, 47-68
- epidemiology, 29-42
- in ICU, 239-262
- natural history, 29, 30, 30
- obstructive sleep apnea and, 24, 120-121
- outcomes
  - factors in, 47
  - survival rates, 31, 32, 33, 45
  - timing of diagnosis and, 47-48
- in pediatric patient, 263-281
- PH syndrome, 14-15
- primary PH (now IPAH), 14-15, 31
- progression of, 30, 48
- radiography, 69-98
  - general findings, 69-71, 70, 93
- screening for, 48, 57
- secondary PH, 14-15
- signs and symptoms, 48-49
- survival rates, 31, 32, 33, 45
- treatment. See also *Treatment*.
  - approach to patient, 99-126, 100
  - goal-oriented approach, 114
  - in ICU, 239-262
  - Non-Group 1 PH, 119-123
  - WHO Group 1 (PAH), 99-119, 100

Pulmonary Hypertension Association, 291

Pulmonary Langerhans cell histiocytosis (PLCH), 87-88, 122

Pulmonary rehabilitation, 211-212, 291

Pulmonary sclerosis, 14-15, 30

Pulmonary vascular remodeling, 25, 80, 268

Pulmonary vascular resistance (PVR), 14, 22, 26
 

- chronic hypoxia and, 268
- estimation from, TRV/VTI [RVOT] ratio, 56
- medications used in lowering, 257, 265
- in newborn, 264
- oxygen, high concentrations of, to lower, 265
- progression in PH, 30
- rise of, in PH/PAH, 30, 30

Pulmonary vascular thrombosis, anticoagulant therapy for, 206-209

Pulmonary vascular tone, 41, 62

Pulmonary vasodilation, 249-251, 257. See also *Vasodilation*.

Pulmonary vasodilator response. See *Vasodilator testing*.

Pulmonary vasodilator therapies, 119-120

Pulmonary veno-occlusive disease (PVOD), 16t, 17, 19, 41, 92
 

- causes and findings, 59t, 80t, 92, 94-95
- diagnosis, vs PAH, 92, 94-95
- mosaic attenuation in, 74

Pulmonary venous pressures, 31-32, 41

Pulmonary vessels, MRI of, 224-225

Pulmonary webs, in CTEPH, 75, 79

Pulse pressure variation (PPV), 247

PVOD. See *Pulmonary veno-occlusive disease*.

PVR. See *Pulmonary vascular resistance*.

Qp:Qs ratio, 81

Radiography, 69-98, 270  
 capillary hemangiomatosis, 92, 96-97  
 chest radiographs, 53, 69-70, 70, 81, 270  
 chronic thromboembolic disease/CTEPH, 74-77, 76, 77t  
 computerized tomography pulmonary angiography (CTPA), 222-224, 224  
 congenital shunts, 77-83, 82-83  
 COPD, 87  
 CT angiography, 71, 72-73, 81, 93  
 general findings for PH, 69-71, 70, 93  
 hepatopulmonary syndrome, 89-90  
 HIV, 88-89  
 idiopathic pulmonary arterial hypertension (IPAH), 72-74, 72-73, 74t  
 mosaic attenuation, 73-74, 75  
 left-sided cardiac disease, 93  
 mediastinal fibrosis, 90, 91  
 mosaic attenuation, 73-74, 75, 93  
 in CTEPH, 74, 77, 79  
 MRI of pulmonary vessels, 224-225  
 phase contrast MRI, 81  
 pulmonary angiography, 58-60, 225, 270  
 CTPA, 222-224, 224  
 pulmonary fibrosis, 83-86, 84-85, 86-87  
 pulmonary Langerhans cell histiocytosis, 87-88  
 pulmonary veno-occlusive disease (PVOD), 92, 94-95  
 risk assessment and, 113t  
 RAP, risk level and, 113t  
 Rate control, 100  
 Raynaud's syndrome, 43, 47  
 Registries and databases, 31, 44, 266  
 REVEAL, 31, 271, 289  
 Remodeling, pulmonary vascular, 25, 80, 268  
 Remodulin, 130t. See also *Treprostinil*.  
 REMS (Risk Evaluation and Mitigation Strategies), 169-172  
 Rescue therapies, 255-256  
 atrial septostomy, 255  
 devices to bypass right heart, 255  
 right ventricular assist devices (RVADs), 255  
 veno-arterial extracorporeal membrane oxygenation (V-AECMO), 255-256  
 Respiratory bronchiolitis interstitial lung disease (RB-ILD), 88  
 Resuscitation, 247-249  
 target CVP for, 243  
 REVEAL Registry, 31, 271, 289  
 REVEAL risk calculator, 32-33, 36-37, 290  
 Rheumatoid arthritis, 18, 38  
 Right atrial enlargement, 70  
 Right atrial pressure (RAP), 54, 288, 289  
 Right end-diastolic ventricular mass, 60  
 Right heart catheterization, 62-64, 65, 270, 289  
 cost of, 69  
 for diagnosis of CTEPH, 225  
 for diagnosis of PH, 48, 62-64  
 in follow-up, 285t, 289  
 PAH risk and, 36  
 Right heart failure, 30, 30. See also *Right ventricle failure*.  
 acute right heart failure, 241, 246t  
 causes of, 241, 246t  
 in chronic PH, 241, 246t  
 Right heart failure (*continued*)  
 diuretics for, 203-204, 213  
 positive pressure ventilation and, 241  
 Right ventricle  
 afterload, 204, 239-241, 240, 251  
 cardiac output, 204, 239  
 dilation of, 56, 247  
 overload, 205, 205, 212, 213, 247, 255  
 perfusion/perfusion pressure, 248, 257  
 preload, 203-204, 239-240  
 central venous pressure (CVP) as surrogate for, 243  
 pressure overload, 47, 220  
 primary function of, 239  
 stroke volume, 239-240, 240, 241  
 ventricular interdependence in PH, 205, 241, 242  
 ventricular volume, relationships of right and left ventricles, 242  
 ventricular volume changes, pressures in, 240-241, 240  
 volume overload, 44, 203, 247, 255  
 Right ventricle failure, 14, 30, 30, 120  
 cardiopulmonary rehabilitation, 211-212  
 causes of, 241, 246t  
 hospitalization for, 206  
 pathophysiology of, in acute PH, 241, 244-245  
 riociguat and, 194  
 triggers of, 241, 246t  
 Right ventricular assist devices (RVADs), 255  
 Right ventricular dysfunction, 40, 247, 269  
 risk in older patients, 31  
 supraventricular tachyarrhythmias, 253-254  
 Right ventricular end-diastolic area, 247  
 Right ventricular end-diastolic pressure (RVEDP), 204, 205  
 Right ventricular function  
 assessment of, 56-57, 56, 288  
 coronary blood flow and, 241  
 digoxin and, 211  
 diuretics and, 204, 205, 213  
 evaluation with cardiac magnetic resonance (CMR), 60-61  
 sepsis and, 254  
 stroke volume and, 239-240, 240, 241  
 Tei-index, 56-57  
 ventricular interdependence in PH, 205, 241, 242  
 ventricular volume changes, 240-241, 240  
 Right ventricular hypertrophy, 69, 83  
 CT angiography of, 71, 72-73  
 electrocardiographic results in, 49-53, 52  
 Riociguat (Adempas), 191-202  
 action mechanism, 191, 201  
 adverse events, 194, 196-197, 199t, 200, 201  
 cautions and contraindications, 200-201, 250  
 as direct sGC stimulator, 191  
 dosing and monitoring information, 199t  
 drug interactions, 200-201  
 FDA approval of, 191  
 history of, 191-193  
 indications for, 104t, 119, 191, 201  
 in combination therapy, 108t, 109t  
 for CTEPH, 100, 119, 191, 201, 229, 233

- Riociguat (Adempas), indications for (*continued*)  
 WHO Group 1 (PAH), 100, 191, 201  
 WHO Group 4 (CTEPH), 100, 119, 191, 201, 229, 233  
 phase 2 trials, 193  
 phase 3 trials, 193-197  
 6MWD, 193-194, 195, 195t, 196, 197, 198t  
 Borg Dyspnea Scale, 194-196, 195t, 198t  
 CHEST-1, 193-196, 194, 195t, 229  
 CHEST-2, 196  
 PATENT-1, 196-197, 197, 198t  
 PATENT-2, 197  
 WHO functional class, 194, 195t, 197  
 pregnancy and, 200  
 when to discontinue, 199t
- Risk assessment, 32-33, 33, 111-115, 112t-113t  
 in pregnancy, 169-172  
 REVEAL risk calculator, 32-33, 36-37, 290
- Risk Evaluation and Mitigation Strategies (REMS), 169-172
- Sarcoidosis, PH associated with, 25, 84-85, 88-89  
 treatment, 122
- Schistosomiasis, PAH associated with, 19
- Scleroderma, 18, 38, 84, 207
- Sclerosis  
 of pulmonary arteries, 14-15, 30  
 systemic, 18, 32
- Selective serotonin reuptake inhibitors (SSRIs), 37
- Selexipeg, 104t, 108t, 131. See also *Prostacyclin therapy*.
- Sepsis, 254-255  
 ICU mortality in PH patients, 254  
 mechanical ventilation for, 247  
 resuscitation in, target CVP, 243
- Septic shock, resuscitation in, target CVP, 243
- SERAPHIN study, 165-167, 167
- sGC stimulators. See *Soluble guanylate cyclase stimulators (sGCS)*.
- Shock, 247-249  
 septic, resuscitation in, 243
- Shunts  
 congenital heart defects, 266-267  
 congenital systemic-to-pulmonary shunts, 19, 20t, 21t  
 causes of, 77-80  
 imaging of, 59t, 77-83, 82-83  
 in CTEPH, 76-77  
 fetal circulation, 264  
 left-to-right, 266-267  
 right-to-left, 269
- Sickle cell disease, 25, 39-40, 122
- Signs and symptoms, 48-49. See also *Symptoms of PH*.
- Sildenafil, 179-188  
 action mechanism, 275  
 adverse effects, 185-187, 186t  
 acute PE, 185  
 nonarteritic ischemic optic neuropathy (NAION), 185-187  
 cautions and contraindications, 121, 122, 187  
 warning for pediatric patients and children, 276  
 drug interactions, 170t, 200-201
- Sildenafil (*continued*)  
 efficacy, 180-181, 182, 187-188  
 6MWD, increase in, 181-183, 182, 185  
 exercise capacity, 181-183  
 functional class, 184  
 hemodynamic effects, 183  
 long-term effect, 184-185  
 for PAH, 180-181, 182  
 PHIRST trial, 181, 182, 183-185, 186t  
 SUPER trial, 181, 182, 183-185, 186t  
 time to clinical worsening, 184  
 generic form, 188  
 indications for, 104t, 179-181, 187-188  
 in combination therapy, 106t, 108t, 109t, 116  
 for critically ill patients with PH, 250  
 for CTEPH, 231-232  
 for PAH, 180-181  
 in pediatric patients, 275-276  
 long-term effect of, 184-185  
 metabolism of, 179, 180, 187  
 in pediatric patients, 275-276  
 STARTS-1 and -2 studies, 275-276
- Sinus venosus ASD, 80
- Sjögren's syndrome, 38
- Sleep apnea, 24, 120-121, 268
- Smooth muscle, cyclic GMP and, 177, 178
- Soluble guanylate cyclase stimulators (sGC stimulators), 191-202.  
 See also *Riociguat*.  
 action mechanism, 191, 201  
 adverse events, 194, 196-197, 199t, 200, 201  
 cautions and contraindications, 200-201  
 dosing and monitoring information, 199t  
 indications for, 100, 191, 201  
 WHO Group 1 (PAH), 100, 191, 201  
 WHO Group 4 (CTEPH), 100, 191, 201, 229, 233  
 nitric oxide/cGMP signaling pathway, 191, 192  
 in overall approach to patient, 100  
 phase 2 trials, 193  
 phase 3 trials, 193-197  
 riociguat, 191-202
- SPAP. See *Pulmonary artery systolic pressure*.
- SSRIs, PAH risk and, 37
- St. John's wort, 37
- STARTS-1 and -2 studies, 275-276
- Statins, ERA interactions with, 171t
- Stroke volume, 239-240, 240, 241
- SUPER trial, 181, 182, 183-185, 186t
- Supportive care for PAH. See *Adjunctive therapy*.
- Supraventricular tachyarrhythmias (SVT), 253-254
- Surfactant, 266
- Survival rates, 31, 32, 33, 45
- Symptoms of PH, 29, 42, 48-49  
 dyspnea, 29, 42, 48, 219-220, 269  
 exercise intolerance, 29, 219-220  
 fatigue, 29, 42, 48  
 in infants and children, 269t  
 risk level and, 112t

- Syncope, 32, 48, 269  
   bosentan and, 159  
   riociguat and, 194  
   risk level and, 112t
- Systemic lupus erythematosus (SLE), 18, 38
- Systemic sclerosis, 18, 32
- Tachyphylaxis, 131, 136
- Tadalafil, 179-188, 275
- adverse effects, 185-187, 186t
  - acute PE, 185
    - nonarteritic ischemic optic neuropathy (NAION), 185-187
- AMBITION trial, 116-118, 117
- cautions and contraindications, 187
- drug interactions, 170t, 200-201
- efficacy, 180-181, 182, 187-188
  - 6MWD, increase in, 181-183, 182, 185
  - exercise capacity, 181-183
  - functional class, 184
  - hemodynamic effects, 183
  - as initial treatment for PAH, 116-118, 117
  - long-term effect, 184-185
  - PHIRST trial, 181, 182, 183-185, 186t
  - SUPER trial, 181, 182, 183-185, 186t
  - time to clinical worsening, 184
- indications for, 104t, 179-181, 187-188
  - in combination therapy, 106t, 108t
    - with ambrisentan, 106t, 116-118, 117
  - for PAH, 179-181
    - long-term effect of, 184-185
    - metabolism of, 179, 180, 187
- TAPSE. See *Tricuspid annular plane systolic excursion*.
- Team, interdisciplinary, 295-296, 297
- Tei-index, 56-57, 288
- Terbogrel, 250
- Thrombin, direct, 208
- Thromboembolism
  - in CTEPH, 222-224, 224, 269
  - in pediatric patients, 269
  - prior history of, 221
- Thrombosis. See also *Pulmonary emboli*.
  - anticoagulant therapy for, 206-209
  - classification (perioperative) with PEA, 226, 227t
  - CTEPH and, 218, 219, 221, 222-224, 224
- Thromboxane, 206
  - thromboxane/prostacyclin ratio, 206
- Thromboxane synthase inhibitor (terbogrel), 250
- Thyroid disease, 26
- Tidal volumes, 251
- Toxin-related PAH, 16t, 18, 35-37, 37t
- Transplantation, lung, 294-295
  - for CTEPH, 228
  - indications for, 100, 102-103, 114
  - mechanical/ventilatory support while waiting for, 255-256
  - patient selection for, 294-295
  - for pediatric patients, 277
- Transpulmonary gradient (TPG), 22-23, 25
- Transthoracic echocardiography (TTE), 53-57, 65, 69
  - in CTEPH, 222
  - in screening for PH, 48, 57
  - sPAP calculation and measurement, 53-54
- Trauma patients, PH and, 254
- Treatment
  - adjunctive therapy and supportive care, 203-216
    - anticoagulants, 206-209
    - cardiopulmonary rehabilitation, 211-212
    - digoxin, 211
    - diuretics, 203-206
      - supplemental oxygen, 209-210
  - approach to PH patient, 99-126
  - classification of PH and, 99, 100, 123
  - combination therapy recommendations, 102-103, 106t, 123
    - sequential drug combination therapy, 108t-109t
  - efficacy
    - adequate clinical response, definition of, 111-115
    - evaluation of, 101-107, 116
      - real-world evaluations, 283-284
    - follow-up recommendations, 283-299
    - therapeutic success, evaluation of, 283-284
    - treatment goals, 284, 284t
  - follow up, 123, 283-299
  - general approach, 99-126
  - goal-oriented approach, 114
  - goals of, 284, 284t
    - functional class improvement, 44, 114, 284t, 286
    - for pediatric patients, 271
  - insurance plans and, 294
  - monotherapy recommendations, 102, 104t-105t, 116
  - natural history and, 29
  - non-improvement with, adding new therapies for, 118, 123
  - obtaining medications for PAH, 294
  - PAH, 99-119, 100
    - adjunctive therapy and supportive care, 203-216
    - calcium-channel blockers, 62, 101
    - ERAs (endothelin receptor antagonists), 153-174
    - ESC/ERS recommendations, 101, 102-103, 104t-106t, 108t-109t
    - general treatment approach, 99-119, 100
    - medication recommendations, 104t-106t, 108t-109t
    - obtaining medications for, 294
    - phosphodiesterase-5 inhibitors, 177-190
    - prostacyclin therapy, 127-152
    - soluble guanylate cyclase stimulators (sGCs), 191-202
  - palliative/end of life care, 292, 297
  - pediatric patients, 271-277
    - specific treatments
      - algorithm for approach, 100
      - calcium-channel blockers, 62
      - ERAs (endothelin receptor antagonists), 153-174
      - ESC/ERS recommendations, 101, 102-103, 104t-106t, 108t-109t
      - phosphodiesterase-5 inhibitors, 177-190
      - prostacyclin therapy, 104t-105t, 127-152
      - soluble guanylate cyclase stimulators (sGCs), 191-202
    - of underlying conditions, 123
  - WHO functional class and, 104t-105t, 106t

- Treatment (*continued*)
- WHO Groups and, 99-126, 100
    - Non-Group 1 PH, 119-123
    - WHO Group 1 (PAH), 99-119, 100
      - medications for Group 1 PAH only, 27, 29, 44
      - treatment recommendations, 101, 102-103, 104t-106t, 108t-109t
  - Treprostinil, 129, 130t, 138-140, 146-148. See also *Prostacyclin therapy*.
    - commercial product names (Remodulin, Tyvaso, Orenitram), 130t
    - dosage, 134-136
    - efficacy, 132, 133-134
      - inhaled treprostinil, 144-146
      - oral treprostinil, 146-147
      - subcutaneous infusion, 139, 140
    - indications for, 104t
      - in combination therapy, 106t, 108t, 116
      - for CTEPH, 230
      - oral treprostinil, 147
      - in pediatric patients, 274
    - infusion pumps, 134, 135, 138
    - in pediatric patients, 274
    - routes of administration, 129, 130t
      - inhalation, 129, 130t, 141-146
        - efficacy of, 144-146
        - half-life, 141, 142
        - nebulizers for, 141, 144, 145
      - intravenous infusion, 129, 130t, 133-134
        - infusion pump for, 134, 135, 138
      - oral, 129, 130t, 146-148
      - subcutaneous infusion, 129, 130t, 138-140
        - adverse effects of, 140
        - for CTEPH, 230
        - disadvantages of, 139-140
        - efficacy of, 139, 140
        - infusion pumps for, 134, 135
        - infusion site discomfort, 139-140
        - vs intravenous infusion, 138-139
    - stability, 130t
      - heat-stable form, 134
  - Tricuspid annular plane systolic excursion (TAPSE), 47, 288
  - Tricuspid regurgitation, 44
  - Tricuspid regurgitation murmur, 220
  - Tricuspid regurgitation pressure gradient, 53, 54
  - Tricuspid regurgitation velocity (TRV), 56
  - TRV/VTI [RVOT] ratio, 56
  - L-tryptophan, 37t
  - Tyvaso, 130t. See also *Treprostinil*.
- Vaccinations, 289-291
- Valvular gradients, 55
- Vane, John, 127, 128
- Vardenafil, 275
  - changes in PVR and, 180
  - drug interactions, with riociguat, 200-201
  - indications for, 104t, 179
- Vascular tone. See *Pulmonary vascular tone*.
- Vasculitis, 26
- Vasoconstriction
  - endothelins/ERAs and, 153, 155, 172
  - hypoxia and, 251
  - thromboxane and, 206
- Vasodilation, 249-251, 257
  - epoprostenol and, 128, 274
  - ERAs and, 154, 155, 160
  - nitric oxide (NO) and, 154, 177, 179, 191, 249-250
  - oxygen and, 210
  - phosphodiesterase-5 inhibitors and, 177, 178, 188, 275
  - prostacyclin and, 206, 266
  - pulmonary vasodilators, 249-251
- Vasodilator response, 102
  - anorectic drug use and, 110
- Vasodilator testing, 62-64, 65, 107-111, 270
  - indications for, 63, 110-111, 271
  - prior to treatment, 107-110
  - risks of, 63
- Vasodilator therapies, 119-120
- Vasopressin, 248, 257
- Vasoreactivity, testing for, 102, 107-110
- Veltri, 130t. See also *Epoprostenol*.
- Veno-arterial extracorporeal membrane oxygenation (V-AECMO), 255-256
- Ventavis, 130t. See also *Iloprost*.
- Ventilation
  - dead space ventilation, 220
  - lung protective ventilation, 251
  - mechanical ventilation, 247, 251
    - avoiding if possible in critically-ill PH patients, 251
    - for PPHN, 266
    - strategies in PH patient, 253
  - positive end-expiratory pressure (PEEP), 253
  - positive pressure ventilation, 251
    - right heart failure and, 241
    - and V/Q relationships, Zone I and Zone II lung, 251, 252
- Ventilation-perfusion (V/Q) scan, 58, 207, 270
  - in CTEPH, 57, 75, 217, 218, 222, 223
  - in PAH, 222
- Ventricular hypertrophy, in CTEPH, 76
- Ventricular interdependence in PH, 205, 241, 242
- Ventricular mass index (VMI), 60-61
- Ventricular septal defects, 77, 82, 267
- Ventricular volume, 242
- Vitamin K, 209
- Volume responsiveness, 246, 255. See also *Stroke volume*.
- Volume status, 243-247, 255, 257
- von Willebrand factor, 206
- Warfarin, 207-209
  - in pediatric patients, 276
- Westermarck sign, 70
- WHO functional classes, 19-21, 104t-105t, 106t, 286
  - risk level and, 112t
- WHO (World Health Organization), classification groups, 14-26, 16t-17t, 44. See also *Classification of pulmonary hypertension*.
- Women, PAH prevalence in, 31, 45

Young patients, 32

Zone I and Zone II lung, 251, 252